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Reverse genetics systems as tools to overcome the
genetic diversity of Lassa virus
Brett Beitzel, Christine E Hulseberg and Gustavo Palacios
Lassa virus is endemic in a large area of sub-Saharan Africa,
and exhibits a large amount of genetic diversity. Of the four
currently recognized lineages, lineages I–III circulate in Nigeria,
and lineage IV circulates in Sierra Leone, Guinea, and Liberia.
However, several newly detected lineages have been
proposed. LASV genetic diversity may result in differences in
pathogenicity or response to medical countermeasures,
necessitating the testing of multiple lineages during the
development of countermeasures and diagnostics.
Logistical and biosafety concerns can make it difficult to obtain
representative collections of divergent LASV clades for
comparison studies. For example, lack of a cold chain in
remote areas, or shipping restrictions on live viruses can
prevent the dissemination of natural virus isolates to
researchers. Reverse genetics systems that have been
developed for LASV can facilitate acquisition of hard-to-obtain
LASV strains and enable comprehensive development of
medical countermeasures.
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Introduction and taxonomic organization of
the Arenaviridae
In the 42 years since the Arenaviridae were formally
recognized as a family [1], the taxon has grown to
recognize 41 member species [2], a quarter of which have
been added within the last two years. Shortly following
the discovery of arenaviruses in boas and pythons,
the Arenaviridae monophyly was split into the
Mammarenavirus and Reptarenavirus in 2014 [3], and, in
2018, the reptile-borne arenaviruses were again separated
into distinct genera, Hartmanivirus and Reptarenavirus [2].
The largest of these three current genera is the
Mammarenavirus, which is further divided into two
distinct groups: the Old World (OW) and the New World
(NW) arenaviruses. In addition to the geographic basis for
their separate groupings, OW and NW arenaviruses are
segregated by their serological, epidemiological, and
phylogenetic relationships. As are the majority of the
other OW arenavirus members of the Mammarenavirus,
Lassa virus (LASV) is a rodent-borne virus whose area of
endemicity is geographically confined to Africa.
Molecular properties of arenaviruses
The genome of the arenaviruses is carried on two RNA
fragments, each with two non-overlapping genes arranged
in opposing orientation. The L RNA fragment encodes
the RNA-dependent RNA polymerase (L) and the RING
finger matrix-like protein (Z), while the S RNA fragment
encodes the glycoprotein (GPC) and the nucleoprotein
(NP). The ribonucleoproteins, which consist of the
viral genome fully encapsidated by NPs, and the L
polymerase, is replication and transcription-competent
[4]. The two genes on each RNA segment are separated
by a 65–200 nucleotide intergenic region (IGR) that
forms a stable hairpin structure(s). While both IGRs
function in transcription termination, there is substantial
difference in their predicted folded structures. The
50-termini and 30-termini of the RNAs have 19–25 highly
conserved nucleotides that form panhandle structures on
each genome segment. These noncoding regions act in cis
with the segment’s IGR to support both genome
replication and transcription [5].
Established and emerging Lassa lineages
Current guidelines for the genetic distinction of arenavi-
rus species require 12% amino acid difference in the NP
sequence [6]. Circulating strains of LASV in West Africa
(some of which, despite exceeding the 12% allowable
difference in amino acid sequence cutoff, are still recog-
nized as LASV species) typically fall into four established
lineages which are highly correlated to the geographical
range of the rodent reservoir for LASV, Mastomys
natalensis. Lineages I–III strains circulate throughout
Nigeria, and lineage IV strains are endemic throughout
the Mano River Union (MRU) region shared by Sierra
Leone, Guinea, and Liberia, roughly 2500 km away.
As additional LASV isolates are collected and studied, an
increasingly complex picture of the genetic diversity of
LASV — particularly in recent years — is developing.
Available online at www.sciencedirect.com
ScienceDirect
www.sciencedirect.com Current Opinion in Virology 2019, 37:91–96
The possible emergence of a fifth lineage was suggested
by Manning et al. in 2015 [7]. Bayesian analysis of L, NP,
and GPC genes of isolates from Mali and the Ivory Coast
suggested that these strains may have split from lineage
IV strains some 250 years ago [7]. In 2016, LASV was
isolated from hitherto unrecognized rodent carriers in
Nigeria (Mastomys erythroleucus and Hylomyscus pamfi)
and Guinea (M. erythroleucus) [8]. Phylogenetic analysis
of both the nucleotide and amino acid sequences on a
newly identified strain isolated from H. pamfi in Kako,
Nigeria indicated that, while clustering nearer the other
Nigerian lineages, this isolate did not belong to any of
them [8]. Yet another possible lineage emerged later in
2016, when a cluster of cases originating in Togo was
sequenced and found to have poorly supported
phylogenies with other LASV strains. The resulting trees,
generated from the L, NP, and GPC sequences, showed
considerable topological variability depending upon
which gene(s) were used in the analysis, and, in all cases,
long branches suggest distant relationships with the other
lineages of LASV [9].
Sources and implications of genetic
diversification in Lassa virus
As with other riboviruses, LASV has an error-prone poly-
merase. Accordingly, the main driving force for the
evolution and diversification of arenaviruses is largely
ascribed to the high mutation rates that occur during
replication [5,10,11]. Examination of the genetic vari-
ability of transmission chains during multiple outbreaks
consistently supports the predominance of rodent-to-
human rather than human-to-human spread [12,13,14];
however, human-to-human transmission may still account
for nearly 20% of human infections [12,13–16].
Reassortment in segmented viruses is another potential
source of diversity, particularly when closely related
strains coinfect a susceptible host. Comparison of
phylograms constructed from full length sequences of
the arenaviral genes suggests that it is unlikely that
natural reassortment has contributed significantly to the
evolutionary history of LASV [17,18]). Nonetheless,
when the L and S segments of 162 LASV isolates from
Nigeria and Sierra Leone were sequenced, three (1.8%)
of these isolates were found to be reassortants [12].
The many challenges associated with developing medical
countermeasures (MCM) against a heterogeneous viral
target such as LASV have long been appreciated. For one,
some evidence suggests that strain pathogenicity may
track with geographical distance. Strains circulating in
the easternmost ranges of the Lassa Belt, that is, lineages
I–III, reportedly have increased pathogenicity relative to
lineage IV; accordingly, case fatality rates are typically
higher in Nigeria than in the MRU [19,20]. By extension,
noted differences in pathogenicity may call into question
whether conclusions based on work using the ‘classic’
prototypical strain, Josiah — the lineage IV strain that
serves as the workhorse for the vast majority of basic and
translational LASV work [21] — will necessarily hold
true for other strains.
An example of potentially critical differences in strain
selection is given by an early LASV vaccine study, in
which the GA391 strain from northern Nigeria (lineage
III) was used to challenge a group of vaccinated outbred
Hartley guinea pigs [22]. While typically only 20% or less
of Hartley guinea pigs infected with Josiah strain LASV
die [23], in this particular study, all of the control guinea
pigs infected with GA391 strain died. Another example of
lineage-dependent responses to an MCM is a 2018 study
evaluating the efficacy of two arenavirus entry inhibitors,
LHF-535 and ST-193 [24]. The inhibitory concentrations
for LHF-535 generally clustered within a 10-fold, sub-
nanomolar range with the exception of the lineage I strain
LP, which was 100-fold less sensitive than all other
strains. Lineage-dependent and even strain-dependent
variability in response to ST-193 was more pronounced,
although, as with LHF-535, the sensitivity of LP strain
LASV to ST-193 was reduced compared to other lineages.
Given the tremendous effort, time, and expense needed
to advance MCMs through clinical trials, tractable
experimental systems are needed to account for LASV’s
formidable genetic diversity.
Reverse genetics
The breadth of LASV diversity can make it difficult to
obtain virus stocks representing a comprehensive
collection of Lassa lineages. Additionally, the relatively
recent development of field-deployable high-throughput
sequencing (e.g. Oxford Nanopore MinION and Illumina
iSEQ) will likely increase the number of viruses for which
genome sequence is available in the absence of natural
isolates. In cases where natural isolates are difficult to
obtain or are nonexistent, reverse genetics can be used to
generate virus stocks for study [25].
Virus reverse genetics systems allow the generation or rescue
of replication-competent viruses from plasmid DNA,
facilitating detailed study of the virus lifecycle. Precise
changes to the virus genome can be made in the plasmid
clones using standard molecular biology techniques, and
viruses can then be rescued from those clones to examine the
resulting changes to the virus phenotype.
The first description of reverse genetics involved the
cloning of the full genome of the RNA bacteriophage
Qb [26]. After cloning a complete copy of the phage
genome cDNA into a plasmid, Taniguchi et al. were able
to rescue viable Qb phage by transforming the plasmid
into susceptible Escherichia coli. This was followed several
years later by the first eukaryotic virus reverse genetics
system for poliovirus [27]. Racaniello et al. cloned the
complete poliovirus genome into a plasmid, and
92 Lassa viruses
Current Opinion in Virology 2019, 37:91–96 www.sciencedirect.com
generated infectious poliovirus upon transfection of the
full genome plasmid into susceptible cells. Both Qb and
poliovirus are positive-stranded RNA viruses, meaning
that introduction of the viral genomic RNA into a host cell
can lead to virus production since the viral proteins can be
translated directly from the genomic RNA by the host cell
machinery. Reverse genetics systems for negative-
stranded RNA viruses are not as straight-forward, since
the deproteinated RNA genome cannot be directly trans-
lated by the host machinery. In order to be transcribed
and replicated, the genome segments of negative-
stranded RNA viruses (NSVs) must be in a ribonucleo-
protein (RNP) complex with the viral nucleoprotein (N)
and the RNA-dependent RNA polymerase (L). Rescuing
NSVs by reverse genetics requires the polymerase and
nucleoproteins to be provided in trans as ‘helper’ proteins.
The helper proteins can either be provided via a
co-infecting helper virus [28], or they can be provided
by expression plasmids. The first described reverse
genetics system for a NSV from cDNA only (i.e. no helper
virus was used) was developed for rabies virus [29].
Schnell et al. showed that infectious rabies virus could
be rescued upon expression of the viral antigenomic RNA
in addition to the N, P, and L proteins in trans (which
make up the viral replication complex).
Arenavirus reverse genetics
Reverse genetics strategies developed for arenaviruses
have generally followed those for NSVs. In the genomic
RNA of arenaviruses, the L and NP genes are encoded in
the antisense orientation, so the proteins that they encode
must be provided in trans in order to generate the
replication and transcription-competent RNP complex.
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Two strategies for arenavirus reverse genetics.
In the four-plasmid arenavirus reverse genetics system (a), L and NP proteins are provided in trans from Pol II or T7-driven expression plasmids.
The genomic (or antigenomic) RNA segments are generated from a T7-driven expression plasmid. A hepatitis delta virus ribozyme sequence (HDV)
generates a precise 30 end of the transcribed RNA. Encapsidation of the genomic RNAs by L and NP kickstarts virus production. In the two-
plasmid system (b), antigenomic RNAs are produced from a T7 expression construct. L and NP proteins are produced by translation of these
antigenomic RNAs, and in turn encapsidate the antigenomic RNAs. The antigenomic RNAs are replicated to produce genomic RNAs which can
then be packaged into progeny virus.
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Development of reverse genetics systems for many NSVs
has usually started with the development of minigenome
or replicon systems. Minigenomes are partial viral
genome segments that contain all of the cis-acting
elements required for replication and transcription, but
in which many or all of the protein coding regions have
been replaced with reporter proteins such as GFP, CAT,
or luciferase. Viral proteins required for replication and
transcription of the minigenome are provided in trans to
drive expression of the encoded reporter protein.
Minigenomes allow for elucidation of the cis-acting and
trans-acting factors required for replication and transcrip-
tion, and can guide the development of full-genome
systems that can generate replication competent viruses.
The first arenavirus minigenome system was developed
for LCMV [30]. Lee et al. designed an S segment mini-
genome in which the NP gene had been replaced by
CAT. In addition, the GPC coding region was removed,
leaving the 50 UTR and IGR. This system showed that
the 50 and 30 UTRs, along with the IGR, were sufficient
cis-acting sequences for CAT expression, and that NP and
L were the minimal viral trans-acting factors for CAT
expression. A similar strategy was used by Hass et al. to
generate a LASV minigenome system that showed NP
and L were also the minimal trans-acting viral proteins
required for replication and expression, and that the 50
and 30 UTRs and the IGR were sufficient cis-acting
sequences. In addition, expression from the LASV
minigenome was shown to be inhibited by ribavirin
and interferon alpha similarly to replicating LASV, indi-
cating that the minigenome system could serve as a
surrogate to LASV in screens to identify antiviral com-
pounds 31]. This LASV minigenome system was also
used for fine mapping of the LASV promoter residing in a
19-nucleotide region of the 50 and 30 termini of the
S segment [32].
Following development of arenavirus minigenome
systems, two general strategies have been developed
for rescuing replication-competent viruses. In the first
(Figure 1a), the L and NP proteins are supplied in trans
via pol II or T7 promoter-driven expression plasmids [33].
RNA analogs of the L and S segments are generated by
expression from T7-driven plasmids and become encap-
sidated by the expressed NP and L proteins to form the
functional RNP complex required for viral replication,
kickstarting production of progeny virions. The second
strategy for arenavirus rescue (Figure 1b) is a two-plasmid
system: one plasmid expressing the antigenomic
L segment, and one plasmid expressing the antigenomic
S segment [34]. Antigenomic RNAs are produced via T7-
driven expression, and L and NP are translated from the
antigenomic RNAs. The L and NP proteins can then
form RNP complexes with the antigenomic RNAs,
facilitating replication into genomic RNAs and generation
of progeny viruses. Both of these strategies have been
used successfully to rescue recombinant LASV [35,36].
Arenavirus reverse genetics systems have been used in
a wide variety of studies. As previously mentioned,
minigenome systems have been used to define the mini-
mal cis-acting and trans-acting factors required for viral
replication, map critical residues of the viral promoter,
and serve as virus surrogates in assays to identify antiviral
compounds [30–32,37–39]. Rescue of replication-
competent recombinant arenaviruses bearing engineered
changes in the genome has allowed studies of virus–host
interactions [36,40], mapping functionally important
regions of the virus genome [34,35,41], and generating
tagged viruses to simplify countermeasure development
[39,42].
Rescue of replication-competent engineered arenaviruses
has also introduced several intriguing strategies for the
generation of attenuated vaccines. Swapping the locations
of GPC and NP on the S segment of LCMV resulted in
strong attenuation in a mouse model, but could protect
from challenge with a virulent strain [43]. Recombinant
LCMVs bearing codon-deoptimized GP or NP are also
attenuated in vivo, and can protect from subsequent
challenge [44,45]. Novel tri-segmented recombinant
arenaviruses have been developed by splitting the
GPC and NP genes onto two separate S segment analogs
[43,46,47]. The tri-segmented recombinant viruses are
only partially attenuated in a mouse model, but surviving
mice develop protective immunity, warranting further
study of the tri-segmented viruses as a vaccine platform
[46]. A similar approach has recently been developed
using non-pathogenic Pichinde virus as a vaccine
vector to express heterologous antigens [48]. Finally, a
hyper-attenuated chimeric Mopeia virus bearing the
LASV GPC has been shown to be protective in a LASV
NHP challenge study [49].
As described above, LASV lineages can potentially
respond differently to medical countermeasures (MCMs),
and also vary in their ability to be detected by current
diagnostic assays [24,50]. These variable responses
highlight the need to test new MCMs and diagnostic
assays against a wide variety of LASV samples from
different lineages. Reverse genetics can facilitate the
acquisition of divergent strains to characterize differences
in lineages response. Future directions involve
the production of diverse isolates of LASV via reverse
genetics to test responses to MCMs and analyze
the sensitivity of diagnostic assays.
Conclusions
LASV genomic diversity reflects the large area of
endemicity throughout sub-Saharan Africa. MCMs
developed against one LASV lineage may not work
against other lineages, highlighting the importance of
testing against divergent strains. Although the advent
of high-throughput sequencing has made it increasingly
easy to obtain full viral genome sequences at the source of
94 Lassa viruses
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an outbreak, dissemination of natural virus isolates to the
research community is becoming increasingly difficult
due to logistical, biosafety, and political concerns.
Reverse genetics systems developed over the past decade
can be used to acquire diverse LASV strains when natural
isolates are difficult to obtain, enabling testing of MCMs
and diagnostic assays against the breadth of LASV
lineages.
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